Migoutine (Colchicine)

Colchicine, the active ingredient in Migoutine, is a microtubule inhibitor presented as an oral tablet for oral use. It treats gout and familial Mediterranean fever in adults, helping to prevent attacks and reduce inflammation. GNH USA supplies Migoutine as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Migoutine (colchicine) acts on inflammatory pathways involved in crystal‑induced arthritis and autoinflammatory disorders. - Gout prophylaxis: reduces the frequency of acute gout attacks in patients receiving urate‑lowering therapy. - Familial Mediterranean fever: prevents recurrent febrile attacks and serositis associated with the hereditary condition. - Acute gout flares: provides symptomatic relief by dampening neutrophil activation during an attack.

Colchicine may cause a range of adverse reactions, from mild gastrointestinal upset to rare but serious toxicities.

Common Side Effects: - Diarrhoea: frequent loose stools, often dose‑related. - Nausea: feeling of sickness, may accompany vomiting. - Abdominal pain: cramp‑like discomfort in the stomach area. - Vomiting: expulsion of stomach contents. - Loss of appetite: reduced desire to eat.

Serious or Rare Side Effects: - Bone marrow suppression: leading to pancytopenia or severe neutropenia. - Rhabdomyolysis: muscle breakdown that can cause kidney injury. - Severe allergic reactions: including anaphylaxis or skin rash. - Hepatic failure: impaired liver function in rare cases. - Multi‑organ failure: systemic toxicity in overdose situations.

Before prescribing Migoutine, clinicians should consider several safety factors. - Dose adjustment: required in patients with renal impairment to avoid accumulation. - Monitor blood counts: regular CBCs are advised because of the risk of bone‑marrow suppression. - Avoid use in severe hepatic disease: impaired metabolism may increase toxicity. - Pregnancy: use only if clearly needed after risk‑benefit assessment. - Drug interactions: review concomitant medications that may raise colchicine levels. - Store at ambient temperature: keep in the original pack, protect from moisture and direct sunlight.

Colchicine interacts with several drug classes that can alter its plasma concentration.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., clarithromycin, ketoconazole): can cause toxic colchicine levels. - P‑gp inhibitors (e.g., verapamil, cyclosporine): increase risk of severe toxicity. - Statins (e.g., simvastatin, lovastatin): heightened risk of rhabdomyolysis.

Moderate Interactions (Monitor Closely): - Diuretics (e.g., thiazides, furosemide): may raise colchicine concentrations. - Moderate CYP3A4 inhibitors (e.g., azithromycin): require dose adjustment. - NSAIDs: additive gastrointestinal irritation and renal effects.